PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives. | PCI is your world leading CDMO, truly spanning the cycle, connecting development and commercialization, de-risking the supply chain providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing development needs throughout the product lifecycle. PCI offers a global network of innovative centers of excellence for the development, manufacturing, packaging, storage, and distribution of life changing therapies. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible. | PCI Pharma is a global CDMO known for delivering seamless integrated end-to-end drug development, manufacturing, and packaging solutions across the product lifecycle with a strong focus on quality, flexibility, and innovation. PCI brings the proven experience that comes with more than 90 successful product launches each year and over five decades in the delivery of CDMO services. Leading technology and continued investment enable us to address global outsourcing needs throughout the product lifecycle. We operate a global network of innovative centers of excellence for the development, manufacturing, drug-device combination assembly, packaging, storage, and distribution of life-changing therapies. Our world- leading sterile fill-finish and lyophilization capabilities combined with specialist contained manufacturing and packaging facilities dedicated to processing highly potent drug products are complemented by a global network of packaging facilities delivering a truly differentiated service. Our aim is simple, to accelerate your product from development to commercialization as efficiently and cost-effectively as possible.
PackGene Biotech
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution. | PackGene Biotech excels as a leader in Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services, focusing on adeno-associated virus (AAV), mRNA, plasmid DNA, and lentiviral vector (LVV) solutions. Catering to early-stage drug discovery, preclinical development, and cell and gene therapy trials, we offer cost-effective, reliable, and scalable production. Our π-Alpha 293 AAV High-yield Platform marks a significant leap in AAV production, increasing yields by up to tenfold and supporting large-scale AAV batches up to 1E+17vg, meeting most commercial and clinical project needs. We also provide scalable, custom plasmid DNA solutions for various project sizes, encompassing end-to-end design, production, and manufacturing. Our GMP plasmid Manufacturing Platform can accommodate production scales from 5L to 200L. Our services extend to comprehensive process development, analytical development, and cell banking support for AAV, LVV, and plasmid projects. Additionally, we specialize in mRNA and LNP solutions, supporting the full spectrum of drug and vaccine development from research to GMP production. Committed to fostering innovation in biotechnology and healthcare, PackGene offers advanced solutions tailored to the evolving demands of the industry.
OXB (formerly Oxford Biomedica)
OXB, formerly Oxford Biomedica, is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, OXB has over 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB’s world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
OranssiBio Ltd.
Oranssibio Ltd. | OranssiBio is a premier Contract Development and Manufacturing Organization (CDMO) strategically headquartered in Shanghai’s Free Trade Zone, specializing in advanced cell and gene therapies. We partner with biotech innovators and research institutions worldwide, delivering comprehensive, end-to-end solutions from early-stage development to clinical supply manufacturing and regulatory-compliant release. Our state-of-the-art, plug-and-play technology platforms support a diverse range of modalities, including: • Plasmid DNA • Lentivirus & Adeno-Associated Virus (AAV) • mRNA Therapeutics • Cell Therapies: CAR-T, TILs, NKs, iPSCs, and MSCs With a focus on quality, speed, and cost efficiency, OranssiBio accelerates the translation of groundbreaking therapies from bench to bedside, empowering our partners to bring life-changing treatments to patients faster and more effectively.
NorthX Biologics
We offer services and support in the development and manufacturing of biologics used in vaccines, gene therapy and other advanced applications. Let’s journey together. | Nestled in Sweden’s life sciences heartland, NorthX Biologics has been at the forefront of biologics manufacturing and process development since 1992. Our rich heritage in Good Manufacturing Practice (GMP) is not just a testament to our enduring commitment to quality but also to the trust that the biotech community has placed in us for nearly three decades. Our expertise spans a comprehensive spectrum of biologics, including plasmids, proteins, mRNA, viral vectors cell therapy, and an array of other advanced therapeutic entities. It is our relentless pursuit of excellence and innovation that led to our recognition in 2021 as a national innovation hub for advanced therapeutics and vaccines by the Swedish Government, a milestone that underscores our role in shaping the future of healthcare. We are more than a CDMO; we are pioneers and partners in the truest sense. At NorthX Biologics, we believe in embarking on a collaborative journey with our clients, navigating the complexities of biologics and growing along the way. Let’s journey together to turn visionary science into life-changing treatments. Visit us to learn more at nxbio.com | Nestled in Sweden’s life sciences heartland, NorthX Biologics has been at the forefront of biologics manufacturing and process development since 1992. Our rich heritage in Good Manufacturing Practice (GMP) is not just a testament to our enduring commitment to quality but also to the trust that the biotech community has placed in us for nearly three decades. Our expertise spans a comprehensive spectrum of biologics, including plasmids, proteins, mRNA, viral vectors cell therapy, and an array of other advanced therapeutic entities. It is our relentless pursuit of excellence and innovation that led to our recognition in 2021 as a national innovation hub for advanced therapeutics and vaccines by the Swedish Government, a milestone that underscores our role in shaping the future of healthcare. We are more than a CDMO; we are pioneers and partners in the truest sense. At NorthX Biologics, we believe in embarking on a collaborative journey with our clients, navigating the complexities of biologics and growing along the way. Let’s journey together to turn visionary science into life-changing treatments.
Northway Biotech
Northway Biotech is a global end-to-end biologics CDMO supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company’s wide-ranging expertise and vertically integrated service offerings translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities, while ensuring full process and product compliance at all stages of research, development, and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius (Lithuania) and Waltham, MA (USA). | Northway Biotech is a global end-to-end CDMO specializing in protein-based biologics and gene therapies. With over 20 years of experience and 180+ successful client programs, we provide integrated solutions – from cell line development to manufacturing cGMP Drug Substance and Drug Product. Our cGMP facilities in Vilnius, Lithuania, and Waltham, MA, support rapid, scalable manufacturing from early development through clinical and commercial phases. Known for scientific excellence, regulatory compliance, and a collaborative approach, Northway Biotech helps clients accelerate biopharmaceutical process development and manufacturing with speed, precision, and flexibility. | Northway Biotech is a leading biologics CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client’s unique needs. For further information, please visit www.northwaybiotech.com.
NJ Bio
NJ Bio, Inc. is a CRO/CDMO specializing in integrated chemistry and biology services for ADCs and other complex bioconjugates. We offer comprehensive solutions spanning discovery, development, characterization, optimization, and bioanalysis, complemented by robust in vitro and in vivo capabilities to support translational decision-making. We provide toxicology, pharmacology, PK, and immunology services to support safety assessment, efficacy profiling, and translational development of ADC and bioconjugate programs. Our expertise in synthetic chemistry, bioconjugation, linker design, and bioanalytical capabilities, ensure seamless support across the entire drug development process and help accelerate ADC programs to become front-line treatments for cancer patients. | NJ Bio, Inc. is a CRO/CDMO that provides high-quality integrated chemistry and biology services to clients mostly from the biotech and pharma sectors. Main service areas include antibody-drug conjugates, bioconjugation, and multistep organic synthesis. The company is headquartered in Princeton, New Jersey, with additional chemistry facilities in Bristol, Pennsylvania. NJ Bio’s facility in Princeton, NJ, occupies ~ 80,000 sq ft of laboratory and office space, with specialized laboratory suites for highly potent compound synthesis, bioconjugation, bioassays, and analytical studies. The facility is very well equipped with instrumentation required for ADC- and bioconjugation-related work. | NJ Bio, Inc. is a CRO/CDMO specializing in integrated chemistry and biology services for ADCs. We offer comprehensive solutions for ADC development, characterization, optimization, and bioanalysis. Our expertise in synthetic chemistry, bioconjugation, linker design, and bioanalytical capabilities, ensure seamless support across the entire drug development process and help accelerate ADC programs to become front-line treatments for cancer patients. | NJ Bio, Inc., is a CRO that provides high-quality integrated chemistry and biology services for ADCs, bioconjugates and nucleic acid-based therapeutics. We strive to be a beacon of excellence in contract research, development and manufacturing by providing cutting-edge biopharmaceutical and advanced chemistry services. Backed by deep expertise in bioconjugation & chemical synthesis, we add value to targeted therapeutic programs through integrated services in conjugation, process development, characterization, and bioanalysis of complex molecules.
NIPPON SHOKUBAI
Nippon Shokubai provides contract manufacturing (CDMO) services for oligonucleotide and peptide active pharmaceutical ingredients (APIs), often referred to as middle molecules. With our advanced, GMP-compliant facilities, we support every stage—from discovery through clinical trials to post-marketing. We also offer comprehensive solutions for manufacturing process development and analytical method development. We are also actively advancing drug delivery systems (DDS) that are critical for middle molecules. This includes developing substances for targeted delivery to disease sites and new biocompatible polymers for DDS, helping to optimize therapeutic outcomes. Capabilities ・Contract manufacturing (CDMO) of oligonucleotide APIs ・Contract manufacturing (CDMO) of peptide APIs ・Contract manufacturing (CDMO) of middle molecule APIs ・Process development ・Analytical development ・Technical transfer for manufacturing ・New biocompatible polymers (DDS and others) ・siRNA-delivery peptides ・Heteroduplex oligonucleotides | Using our own technology, we at NIPPON SHOKUBAI manufacture ethylene oxide, acrylic acids, catalysts, superabsorbent polymers and so on. We will continue to launch new products in ICT, Life Science and Energy & Environment fields and perpetuate corporate mission of “TechnoAmenity: Providing prosperity and comfort to people and society, with our unique technology”.
Mexico Pavilion (MEX BIO)
MEX BIO Pavilion – BIO International Convention 2026 The MEX BIO Pavilion represents Mexico’s coordinated national presence at the BIO International Convention, the world’s leading global event for biotechnology and life sciences. Since 2022, Mexico has maintained a continuous and growing participation at BIO through a national pavilion, reflecting the strategic importance of the life sciences sector for the country and the sustained collaboration between industry, government, academia, and innovation stakeholders. MEX BIO serves as a platform for international engagement, business development, and ecosystem positioning, bringing together Mexican pharmaceutical and biotechnology companies, CROs and CDMOs, startups, research institutions, clusters, and public agencies. Over the past four editions, more than 50 Mexican organizations have participated, positioning Mexico as a key life sciences hub in Latin America and a reliable partner for global collaboration. The Pavilion is designed to go beyond a traditional exhibition space. Through a curated program of activities—including MEX BIO Day, MEX BIO Talks, MEX BIO Walks, and high-level institutional engagements—the Pavilion facilitates targeted meetings, strategic dialogues, and direct interaction with international partners, investors, and decision-makers. A dedicated digital platform and ecosystem wall further enhance visibility and extend engagement before, during, and after the Convention. Mexico’s presence at BIO reflects the country’s commitment to innovation, advanced manufacturing, regulatory dialogue, and international cooperation in life sciences. The MEX BIO Pavilion offers global stakeholders a unique entry point to explore Mexico’s capabilities, connect with its innovation ecosystem, and identify opportunities for collaboration, investment, and market access in one of the region’s most dynamic life sciences environments.